INT199430

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2005
Last Reported 2007
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.48
Pain Relevance 0.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (LTA) extracellular space (LTA) extracellular region (LTA)
cell-cell signaling (LTA)
LTA (Homo sapiens)
Pain Link Frequency Relevance Heat
corticosteroid 114 99.32 Very High Very High Very High
Inflammation 41 96.92 Very High Very High Very High
agonist 6 76.96 Quite High
Inflammatory marker 3 53.48 Quite High
antagonist 24 50.00 Quite Low
Onset of action 6 34.56 Quite Low
cytokine 15 32.48 Quite Low
aspirin 3 16.16 Low Low
Inflammatory response 11 5.00 Very Low Very Low Very Low
withdrawal 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Asthma 234 99.44 Very High Very High Very High
INFLAMMATION 58 96.92 Very High Very High Very High
Voice Disorders 3 57.76 Quite High
Candida Infection 3 55.76 Quite High
Syndrome 567 50.00 Quite Low
Hyperplasia 3 35.80 Quite Low
Airway Remodeling 12 34.32 Quite Low
Rhinitis 27 24.56 Low Low
Chronic Disease 3 18.32 Low Low
Increased Venous Pressure Under Development 69 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
LTA and LPS, at the concentration range of 10 ng/ml to 10 ?
Regulation (range) of LTA
1) Confidence 0.11 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768757 Disease Relevance 0 Pain Relevance 0
However, there is data suggesting that LT concentration is not significantly affected by GCS use (Wenzel et al 1997; Pavord et al 1999).
Neg (not) Regulation (affected) of LT
2) Confidence 0.04 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.78 Pain Relevance 0.27
The most recent updates continued the same role for LT modifiers in mild persistent asthma, but added a role for them in moderate persistent asthma as alternative add-on treatment in patients inadequately controlled on low-to-medium dose (88–660 ?
Regulation (role) of LT associated with asthma
3) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.91 Pain Relevance 0.24
Also, according to the 1997 guidelines, the LT modifiers were considered as an alternative to low doses of ICS, cromolyn, nedocromil, or theophylline for patients ?
Regulation (alternative) of LT associated with corticosteroid
4) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.79 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox